January 25, 2023

Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor

– Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January...

Read More
November 29, 2022

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team

– Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and...

Read More
October 19, 2022

ECTRIMS 2022, October 26-28, Amsterdam, The Netherlands

38th Congress of the European Committee for Treatment and Research in Multiple...

Read More
October 18, 2022

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

– Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise...

Read More
September 22, 2021

Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

Leuven, Belgium, 22 September 2021 – Rewind Therapeutics (“Rewind”), a private Belgian...

Read More
September 2, 2020

Rewind Therapeutics appoints Kees Been as Non-Executive Director

Leuven, Belgium, 2 September 2020 – Rewind Therapeutics (“Rewind”), a private Belgian...

Read More
This website uses cookies to ensure you get the best experience on our website. Get more details by clicking on the Button below.